| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.0K | 17.8% | 32.0% |
| Total Income | 2.0K | 17.9% | 32.0% |
| Expenditure | 1.8K | 17.1% | 32.7% |
| PBT | 197.69 | 25.5% | 26.2% |
| Net Profit | 148.31 | 25.8% | 26.5% |
| OPM | 13.19% | 0.06pp | 1.55pp |
| NPM | 7.43% | 0.47pp | 0.32pp |
| EPS | 2.96 | 26.0% | 16.5% |
Record Delivery Beats Full-Year Guidance—Now the Street Tests Execution
Time Technoplast delivered Q2 PAT of ₹148 Cr (+27% YoY), beating its own full-year PAT growth guidance of 23–24% in a single quarter. Management raised guidance. The call reveals why—and where the real risk sits.
₹148.3 Cr
+26.5% YoY; beat guidance in one quarter
>25% growth
Raised from 23–24%; Q2 already at 27%
+29%
H1 FY27; at high end of 25–30% guidance
₹2,500 Cr
3-year target; timing mid-2027
On paper it reads as a blowout: Q2 net profit of ₹148.3 Cr represents 27% year-on-year growth, which already exceeds the company's guided full-year PAT growth of 23–24%. Management responded by raising guidance to >25% on the call. But the real story is not the headline—it's the gap between what was guided and what was delivered, and why that gap means execution is now the credibility test, not the plan.
What the quarter actually delivered
Revenue of ₹1,994.2 Cr is squarely where guidance pointed: full-year ₹2,000 Cr at the start of the year implied Q2 in the ₹1,900–₹2,000 Cr range, and that's what landed. The win is not the headline revenue—it's the mix and profitability. Composite products, the high-margin segment, delivered +29% growth in H1, hitting the top end of the 25–30% guidance band. This is organic (not a one-time item; not inventory MTM). Industrial packaging is steady. PE pipe, the pressure point, grew in line with 20–25% guidance despite monsoon delays in H1. The EBITDA margin stayed at 13.2%, consistent with prior year, and the company carried through to a record EBITDA of ₹265 Cr.
Management's claims vs. what holds up
Net sales increased 32% YoY
Delivered ₹1,994.2 Cr vs. ₹1,512 Cr prior year = 31.8% growth
Supported
PAT ₹146–148 Cr in Q2
Delivered ₹148.3 Cr (within guidance range, +26.5% YoY vs. 23–24% full-year guide)
Supported; beat full-year guidance in Q2 alone
EBITDA ₹265 Cr
Implied from OPM 13.2% on ₹1,994.2 Cr = ₹262.5 Cr; matches stated ₹265 Cr
Supported
Composite products +29% in H1
High end of 25–30% guidance; strong order book ₹210 Cr validates demand
Supported; segment is running hot
Volume growth 13% H1, tracking 15% full-year target
On pace with prior 'above 15% FY27' minimum guidance; Q2 delivery consistent
Supported; on track
What changed on this call
Guidance was raised. EBITDA growth guidance moved from 19–20% to >20%; PAT growth from 23–24% to >25%. This is a material signal: management is not hedging after a strong quarter, but leaning in. The justification is composite volume momentum and automation efficiency gains now visible in H1 run-rate, plus margin mix improving as capex cycle completion lifts capacity utilization.
Hydrogen opportunity was quantified. A ₹2,500 Cr 3-year hydrogen business pipeline is now on the table, backed by concrete orders: ₹2.5 Cr (NTPC hydrogen locomotive), ₹83 Cr (PSU CNG cascades). The company has PESO approval for Type 4 hydrogen cylinders—a first-mover advantage in India. But the timing is external: demand clarity is pegged to mid-2027, dependent on government order placement and renewable energy initiatives. This is not a misfire; it's a structural tailwind with uncertain near-term unlock.
Ebullient acquisition was deferred. The ₹220 Cr QIP-funded acquisition of Ebullient Plastomers (IBC/packaging synergies) is now on hold pending geopolitical stabilization. This is prudent (West Asia uncertainties warranting caution), but it delays consolidation-driven synergies (7.5–10% EBITDA uplift) by 2–3 years. Capex roadmap remains: ₹350 Cr FY26-27 on track (₹174 Cr H1 spent), normalizing to ₹200–250 Cr post-2027.
The bull-bear ledger
Record Q2 PAT (₹148.3 Cr) beats full-year guidance in one quarter—execution credibility confirmed
Composite segment +29% (H1), at high end of guidance; ₹210 Cr order book signals sustained demand
Hydrogen Type 4 cylinders PESO-approved; ₹2,500 Cr 3-year pipeline with NTPC & PSU orders embedded
Capex cycle completion (Morai 480 cascades, Greenpeace conical done) enables margin expansion 13% → 15.5% target
Management raised EBITDA/PAT guidance after strong Q2; not hedging despite upside surprise
PE pipe margin compressed to 10–12% (raw material inflation 30–40%, EPC contractor cost-pass-through dependency)
Middle East business down 25% H1 due to geopolitical tension; 11% of overseas revenue at risk
Hydrogen demand realization is external-dependent (government order timing, regulatory approvals); mid-2027 clarity
Ebullient acquisition deferred; consolidation synergies delayed 2–3 years; capex/investment flexibility constrained
Polymer price volatility remains; 20–25 day cost-pass-through lag effective but not foolproof if cycles shorten
Risks, ranked by how much they should concern a holder
Hydrogen commercialization timing (external approval dependency)
Medium₹2,500 Cr 3-year pipeline and 5-year ₹5,000 Cr composite revenue targets hinge on government order placement and regulatory approval cycles (PESO, ministry). Mid-2027 clarity is a placeholder; delay pushes payback out and defers capex ROIC realization. Market is pricing stock at ₹189.69; high hydrogen leverage could amplify drawdown if timing slips.
PE pipe margin compression (EPC cost-pass-through risk)
MediumRaw material inflation (30–40%) is being passed to EPC contractors, not fully to end customers. If EPC absorbs costs or government budgets don't expand, Time's 10–12% PE pipe margin is at risk. PE pipe is 40% H1 / 60% H2 seasonal; H2 margin realization will be a key indicator.
Geopolitical exposure (West Asia / Middle East tensions)
MediumMiddle East business (11% of overseas revenue, 4% of total) down 25% H1. Further escalation in the region could extend the headwind. Overseas is 36% of revenue; MENA concentration creates earnings volatility not fully hedged by company actions.
Polymer price volatility & cost-pass-through mechanism failure
LowThe 20–25 day lag between polymer cost inflation and customer price revisions is currently holding, but if commodity cycles accelerate or customers push back, margin compression could hit 13.2% EBITDA margin unexpectedly. Current inflationary environment makes this plausible but not imminent.
Capex execution and ramp delay
LowMorai plant (480 cascades, ₹430 Cr capex) is ramping post-completion; 6–8 month commercialization cycle assumed. Any construction/commissioning slip could delay 15% volume growth realization and margin improvement timeline.
How the street is positioned
The stock is trading at ₹189.69 as of the report date, sitting -26.1% below its all-time high of ₹256.8, but +23.5% above its 52-week low of ₹153.63. Price is above the SMA20 (₹172.04), SMA50 (₹177.64), and SMA200 (₹182.56), but RSI at 61.6 signals neutral momentum—neither overbought nor oversold. Volume is increasing, suggesting growing interest but not yet conviction.
On the ownership front, FII holdings declined to 8.53% (Q1 FY27) from 10.88% (Q4 FY26), a -2.35 percentage-point drop. This is meaningful: foreign money is trimming exposure ahead of the earnings season and into geopolitical uncertainty. DII holdings ticked up marginally (+0.2pp to 17.57%), and promoters remain steady at 47.56%. The FII outflow is not panic-selling, but it signals hesitation on the hydrogen upside narrative and/or concern over Middle East headwinds. This divergence matters: if the company executes on capex completion and composite growth, FII re-entry becomes a catalyst.
The drawdown from ATH (-26%) in a backdrop of record earnings delivery is a red flag or an opportunity depending on your read: the market is pricing in either hydrogen delay or PE pipe margin erosion, not baseline growth. If guidance is met and hydrogen orders start flowing by mid-2027, the stock could re-rate. If PE pipe margins compress further or Middle East escalates, the 52-week low becomes a risk.
What to watch next
1 · H2 FY27 PE pipe volume and margin realization
PE pipe is historically 60–65% of annual business in H2 (post-monsoon seasonal strength). Watch order inflow in Q3 and whether margins hold at 10–12% or compress further as raw material inflation stalls. This will clarify whether government Jal Jeevan incentives are offsetting EPC cost-pass-through headwinds.
2 · Morai plant composite cascade ramp and EBITDA margin trajectory
Greenpeace is commercialized; Morai ramp-up (6–8 months, 480 cascade capacity) is the marginal EBITDA uplift driver. Watch Q3/Q4 FY27 composite volume contribution and whether consolidated EBITDA margin trends toward the 15.5% target. This validates the capex payback thesis.
3 · Hydrogen order pipeline concretization (mid-2027)
Management pegged mid-2027 for hydrogen demand clarity from India's renewable energy and LPG supply initiatives. Watch for government order announcements, NTPC/PSU cascade procurement timelines, and international hydrogen inquiries from European exhibitions. This will signal whether ₹2,500 Cr 3-year pipeline is on track or faces delay.
Time Technoplast delivered a record quarter that beat its own full-year profit guidance in Q2 alone. This is execution, not luck, and management's decision to raise guidance reflects conviction, not caution. But the stock's 26% drawdown from its all-time high, combined with FII exit, suggests the street is hedging on hydrogen timing and PE pipe margin pressure. The next step-change happens when capex completes (margin expansion) and hydrogen orders materialize (top-line acceleration). Until then, expect the stock to consolidate—steady execution on composite and PE pipe segments is priced in, but the upside (hydrogen + 15.5% EBITDA margin) is discounted.
The single number to track from here: EBITDA margin in Q3/Q4 FY27. If it trends toward 13.8–14.2% (indicating capex completion leverage), the stock re-rates. If it holds at 13.2% (PE pipe compression offsets composite mix), the market's caution is justified, and downside risk is real.
Record PAT, raised guidance, hydrogen tailwinds offset geopolitical headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Hit composite guidance (29% vs 25-30%), volume on track (13% H1, 15% FY27 target), revenue guidance met precisely (₹2,000 Cr vs ₹1,994.2 Cr delivered). No prior misses mentioned.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Time Technoplast delivered record Q2 PAT of ₹148 Cr (+27% YoY), beating guided 23-24% PAT growth expectation in Q2 alone—demonstrating execution ahead of curve. Raised EBITDA/PAT guidance to >20%/>25% on volume momentum. Capex cycle completion unlocks margin expansion (13% → 15.5% target) and hydrogen opportunity (₹2,500 Cr 3-year pipeline). Key risk: geopolitical headwinds (Middle East -25%, West Asia uncertainty) and PE pipe pricing pressure, though government infrastructure support improving trajectory.
₹1994.2 Cr
Revenue · +32% YoY₹148.3 Cr
Reported PAT · +26.5% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Net sales increased by 32%
METDelivered YoY revenue growth: 32.0% (₹1994.2 Cr vs ₹1512 Cr prior year)
PAT INR146 crores in Q2
METDelivered PAT: ₹148.3 Cr (1.6% variance, likely rounding)
EBITDA INR265 crores
METImplied from OPM 13.2% = ₹262 Cr (matches stated ₹265 Cr closely)
Composite products grew 29% in H1
METGuidance was 25-30%; 29% is at high end, aligned with strong order book (₹210 Cr)
Volume growth 13% in first half, targeting 15% full year
METOn track with prior 'above 15% FY27' guidance; delivery corroborates achievability
Earnings quality
What changed since the last call
EBITDA growth guidance
UpgradePrior: 19-20% FY27. Now: >20% (raised floor). Driven by composite volume momentum, margin mix, automation efficiency gains.
PAT growth guidance
UpgradePrior: 23-24% FY27. Now: >25% (raised floor). Q2 delivered +26.5% YoY, proving visibility.
Capex clarity
NeutralMaintained ₹350 Cr FY26-27 (H1 = ₹174 Cr on track). Greenpeace conical & Morai ramp achieved. Normalizing post-2027 to ₹200-250 Cr as prior guided.
Ebullient acquisition hold
WithdrawnDecision to pause pending geopolitical stabilization; ₹220 Cr OIP proceeds held in abeyance, strategic consolidation delayed 2-3 years.
Hydrogen commercialization window
NewMid-2027/end-2027 hydrogen demand clarity expected; ₹2,500 Cr 3-year pipeline target articulated, leveraging PESO-approved Type 4 cylinder capability.
The Q&A
Analysts pressed hard on PE pipe margin compression (Aaryan Vadaria), hydrogen timing (Jatin), and cost-saving realization (Jatin). Management held firm: PE pipe margin at 10-12% defended as EPC-controlled, hydrogen approvals in hand, automation payback <1.5 years. No sign of guidance hedging; confident and detailed on execution roadmap, though hydrogen commercialization timing acknowledged as external-approval dependent.
Growth capex, Morai capacity — Jatin, SVAN Investments
AnsweredMorai capacity 480 cascades, ₹350 Cr FY26-27 capex plan on track (₹174 Cr H1). Expansion takes 6-8 months post-completion. 15% volume minimum 3-year commitment.
Cost savings, consolidation benefits — Jatin, SVAN Investments
Answered₹11 Cr power savings (solar + supply agreement). Consolidation 7.5-10% EBITDA uplift; 13% margin can expand to 15.5% next year from automation, re-engineering, unit consolidation.
Composites business drivers — Shaurya Shah, Equirus Securities
AnsweredLPG shortage, government new-connection mandates, hydrogen demand, oxygen cylinders, CNG cascades. Market size large; company only supplier of Type 4 PESO-approved cylinders in India. Capacity constraint being lifted; product development ongoing (CNG 250-350L variants, hydrogen 14.2 kg variant).
QIP funds usage, PE pipe challenges — Aaryan Vadaria, Acquitas Investments
PartialEbullient acquisition on hold (geopolitical uncertainty); ₹220 Cr OIP pending. PE pipe: government pricing incentives improving situation; ₹375 Cr current-year orders; margins defended at 10-12% (raw material cost pass-through to EPC contractors).
Inventory valuation gains — Aditya Sahu, 3P Investment Managers
AnsweredNo material gains. Company follows 65-70 day inventory cycle (local manufacturers); forex hedging tight policy; exchange rate fluctuations booked monthly, no large one-time gains.
Guidance
FY27: 15% volume growth minimum (all of year), revenue guided by segment mix
HighH1 achieved 13% volume (on track); composite 25-30% (at 29%), packaging 12%, PE pipe 20-25% (improving). Overseas 13-15% (86% utilization).
Composite segment ₹5,000 Cr revenue potential (5 years) from ₹430 Cr capex
Medium4x revenue leverage; dependent on hydrogen demand materialization, government order placement timing, and capex completion ramp.
Hydrogen business ₹2,500 Cr (3-year estimate) in testing/development
MediumOrders secured (₹2.5 Cr NTPC, ₹83 Cr PSU), but regulatory approvals and supply-chain buildout uncertain. Mid-2027 demand clarity expected.
EBITDA growth >20% FY27 (raised from 19-20%)
HighH1 EBITDA +17%; composite mix expansion and automation efficiency driving uplift. Polymer price pass-through (20-25 day lag) enabling margin stability.
PAT growth >25% FY27 (raised from 23-24%)
HighQ2 delivered +27% YoY; H1 +25% YoY already on target. Finance cost reduced post-QIP debt repayment.
EBITDA margin 13% → 15.5% next year (H2 FY27 → FY28)
MediumContingent on consolidation completion (7.5-10% uplift), automation efficiency gains, and composite product mix expanding.
FY26-27: ₹350 Cr (consolidation phase, Morai + Greenpeace)
HighH1 spent ₹174 Cr (50% pace); projects (Greenpeace completed, Morai ramping) on track. Non-core asset monetization (₹134 Cr identified) offsetting net spend.
Post-2027 normalizing to ₹200-250 Cr (maintenance + brownfield)
HighCapex cycle completing; maintenance capex sufficient post-Morai expansion. Asset 1.25M sqft land near Morai allocated.
Risks the call surfaced
Geopolitical exposure (Middle East)
MediumMiddle East business down 25% H1 due to West Asia conflict; accounts for ~11% overseas revenue (36% of total). Further escalation could materially reduce growth.
PE pipe pricing power erosion
MediumPE pipe raw material costs surged 30-40% from base; company margins 10-12% constrained by EPC contractor control of pricing. If government doesn't raise project budgets or EPC absorbs costs, margins compress.
Hydrogen demand realization uncertainty
Medium₹2,500 Cr 3-year hydrogen business and ₹5,000 Cr 5-year composite revenue targets depend on government order placement, which has geopolitical/budget cycles. Regulatory approval timelines (PESO, ministry) external to company control.
Polymer price volatility
LowDomestic PE/PP prices continue upward trajectory; company passes cost to customers with 20-25 day lag. If lag shortens or pass-through fails, EBITDA margin (currently 13.2%) compresses.
Capex execution delay risk
LowMorai expansion completion dependent on construction/commissioning timelines; 6-8 month ramp anticipated. If delayed, volume growth targets (15% FY27) at risk, delaying ROIC improvement.
Management
Score 8/10. Highly detailed, granular segment/geography breakdowns. Transparent on challenges (geopolitical, monsoon impact, polymer volatility). Clear capex roadmap with project milestones. Hydrogen timeline acknowledged as external-approval dependent (appropriate caveating). Strong track record: Greenpeace conical completed on schedule, Morai ramping, TPL Plastech merger on track for April 2026. Q2 delivered ₹148 Cr PAT vs ₹146 Cr guided (+27% vs 23-24% full-year target)—ahead of curve. No misses cited.
1 · H2 FY27
PE pipe pricing normalization; government Jal Jeevan pushes orders (60-65% historical H2 seasonal strength)
2 · Q3-Q4 FY27
Morai plant composite cascade ramp-up, hydrogen commercialization order finalization (₹400+ Cr capex completion)
3 · Mid-2027
Hydrogen demand trajectory clarity from India's renewable energy / LPG supply initiatives
Key risk: geopolitical headwinds (Middle East -25%, West Asia uncertainty) and PE pipe pricing pressure, though government infrastructure support improving trajectory.